Development of new cyclic plasmin inhibitors with excellent potency and selectivity.
The trypsin-like serine protease plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss. The optimization of our recently described substrate-analogue plasmin inhibitors, which were cyclized between their P3 and P2 side chains, provided a new series with improved efficacy and excellent selectivity. The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K(i) values >1 μM were determined for nearly all other tested trypsin-like serine proteases, with the exception of trypsin, which is also inhibited in the nanomolar range. Docking studies revealed a potential binding mode in the widely open active site of plasmin that explains the strong potency and selectivity profile of these inhibitors. The dialkylated piperazine-linker segment contributes to an excellent solubility of all analogues. Based on their overall profile the presented inhibitors are well suited for further development as injectable antifibrinolytic drugs.
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12
CHEMICAL CHEMICAL CHEMICAL GENE-N GENE-Y GENE-Y GENE-N GENE-Y GENE-N GENE-N GENE-Y GENE-Y
serine serine piperazine serine protease plasmin plasmin trypsin plasmin trypsin-like serine proteases trypsin plasmin plasmin